Impact of brain death on ischemia/reperfusion injury in liver transplantation

Current Opinion in Organ Transplantation

Volumn 19, Issue 2, 2014, Pages 108-114

  Dziodzio, Tomasz ^a   Biebl, Matthias ^a   Pratschke, Johann ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

brain death; ischemia reperfusion injury; liver transplantation

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NITRIC OXIDE; TACROLIMUS; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; BRAIN DEATH; CYTOKINE RELEASE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KUPFFER CELL; LIVER FIBROSIS; LIVER TRANSPLANTATION; NATURAL KILLER CELL; NATURAL KILLER T CELL; ORGAN DONOR; ORGAN PRESERVATION; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; TISSUE INJURY;

BIOLOGICAL MARKERS; BRAIN DEATH; HUMANS; LIVER; LIVER TRANSPLANTATION; REPERFUSION INJURY; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS;

EID: 84897115234     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000061     Document Type: Review

References (68)

1. Silberhumer GR, Rahmel A, Karam V, et al. The difficulty in defining extended donor criteria for liver grafts: the Eurotransplant experience. Transpl Int 2013; 26:990-998.
2. Mittler J, Pascher A, Neuhaus P, Pratschke J. The utility of extended criteria donor organs in severely ill liver transplant recipients. Transplantation 2008; 86:895-896.
3. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Physiol Gastrointest Liver Physiol 2003; 2:G15-G26.
4. Bilzer M, Gerbes AL. Preservation injury of the liver: mechanisms and novel therapeutic strategies. J Hepatol 2000; 2:508-515.
5. Lentsch AB, Kato A, Yoshidome H, et al. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology 2000; 32:169-173.
6. Shivalkar B, Van Loon J, Wieland W, et al. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation 1993; 87:230-239.
7. Power BM, Van Heerden PV. The physiological changes associated with brain death-current concepts and implications for treatment of the brain dead organ donor. Anaesth Intensive Care 1995; 23:26-36.
8. Pratschke J, Wilhelm MJ, Kusaka M, et al. Brain death and its influence on donor organ quality and outcome after transplantation. Transplantation 1999; 67:343-348.
9. Novitzky D. Detrimental effects of brain death on the potential organ donor. Transplant Proc 1997; 29:3770-3772.
10. Zhai Y, Busuttil RW, Kupiec-Weglinski JW, et al. Liver ischemia and reperfusion injury: new insights into mechanisms of innate-adaptive immunemediated tissue inflammation. Am J Transplant 2011; 11:1563-1569.
11. Novitzky D, Cooper DK, Rosendale JD, et al. Hormonal therapy of the braindead organ donor: experimental and clinical studies. Transplantation 2006; 82:1396-1401.
12. Salim A, Martin M, Brown C, et al. Using thyroid hormone in brain-dead donors to maximize the numbers of organs available for transplantation. Clin Transplant 2007; 21:405-409.
13. Kusaka M, Pratschke J, Wilhelm MJ, et al. Activation of inflammatory mediators in rat renal isograft by donor brain death. Transplantation 2000; 69:405-410.
14. Van der Hoeven JA, Ploeg RJ, Postema F, et al. Induction of organ dysfunction and up-regulation of inflammatory markers in the liver and kidneys of hypotensive brain dead rats: a model to study marginal organ donors. Transplantation 1999; 68:1884-1890.
15. Olinga P, van der Hoeven JA, Merema MT, et al. The influence of brain death on liver function. Liver Int 2005; 25:109-116.
16. Wilhelm MJ, Pratschke J, Beato F, et al. Activation of the heart by donor brain death accelerates acute rejection after transplantation. Circulation 2000; 102:2426-2433.
17. Pratschke J, Wilhelm MJ, Kusaka M, et al. Accelerated rejection of renal allografts from brain dead donors. Ann Surg 2000; 232:263-271.
18. Leithead JA, Armstrong MJ, Corbett C, et al. Hepatic ischemia reperfusion injury is associated with acute kidney injury following donation after brain death liver transplantation. Transpl Int 2013; 26:1116-1125.
19. Beecher HK, Adams RD, Barber AC, et al. A definition of irreversible coma. Report of the Ad Hoc Committee of the Harvard Medical School to Examine the Definition of Brain Death. JAMA 1968; 205:337-340.
20. Simas R, Silva IA, Menegat L, et al. Inhibition of autonomic storm does not improve microcirculatory impairment and inflammatory response in brain dead rats. Transpl Int 2013; 26 (Suppl 2):204.
21. Lentsch AB, Kato A, Yoshidome H, et al. Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury. Hepatology 2000; 32:169-173.
22. Tsung A, Klune JR, Zhang X, Jeyabalan G. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 2007; 204:2913-2923.
23. Tsoulfas G, Takahashi Y, Ganster RW, et al. Activation of lipopoly-saccaride signaling pathway in hepatic transplantation preservation injury. Transplantation 2002; 74:7-13.
24. Peng Y, Gong JP, Liu CA, et al. Expression of toll-like receptor 4 and MD-2 gene and protein in Kupffer cells after ischemia-reperfusion in rat liver graft. World J Gastroenterol 2004; 10:2890-2893.
25. Peralta C, Jiménez-Castro MB, Gracia-Sancho J. Hepatic ischemia and reperfusion injury: Effects on the liver sinusoidal milieu. J Hepatol 2013; 59:1094-1106.
26. Lappas CM, Day YJ, Marshall MA, et al. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med 2006; 203:2639-2648.
27. Feng L, Cheng F, Ye Z, et al. The effect of renal ischemia-reperfusion injury on expression of RAE-1 and H60 in mice kidney. Transplant Proc 2006; 38:2195-2198.
28. Beldi G, Banz Y, Kroemer A, et al. Deletion of CD39 on natural killer cells attenuates hepatic ischemia/reperfusion injury in mice. Hepatology 2010; 51:1702-1711.
29. Ritschl P, Oberhuber R, Fabritius C, et al. Donor brain death results in differentially modulated immune activation in solid organs. Transpl Int 2013; 26 (Suppl 2):14.
30. Weiss S, Kotsch K, Francuski M, et al. Brain death activates donor organs and is associated with a worse I/R injury after liver transplantation. Am J Transplant 2007; 7:1584-1593.
31. Muruve NA, Helling TS, Luger AM, et al. Effect of donor brain death duration on graft outcome. Transpl Proc 2001; 33:2980-2981.
32. Blasco V, LeoneM, Bouvenot J, et al. Impact of intensive care on renal function before graft harvest: results of a monocentric study. Crit Care 2007; 11:R103.
33. Giral M, Bertola JP, Foucher Y, et al. Effect of brain-dead donor resuscitation on delayed graft function: results of a monocentric analysis. Transplantation 2007; 83:1174.
34. Nijboer WN, Moers C, Leuvenink HG, et al. How important is the duration of the brain death period for the outcome in kidney transplantation? Transpl Int 2011; 24:14-20.
35. Kunzendorf U, Hohenstein B, Oberbarnscheid M, et al. Duration of donor brain death and its influence on kidney graft function. Am J Transplant 2002; 2:292.
36. Giral M, Bertola JP, Foucher Y, et al. Effect of brain-dead donor resuscitation on delayed graft function: results of a monocentric analysis. Transplantation 2007; 83:1174-1181.
37. Lznerowicz A, Chudoba P, Kamińska D, et al. Duration of brain death and cold ischemia time, but not warm ischemia time, increases expression of genes associated with apoptosis in transplanted kidneys from deceased donors. Transplant Proc 2011; 43:2887-2890.
38. Weissenbacher A, Oberhuber R, Weissenbacher S, et al. Significant impact of prolonged brain death duration on patient survival after kidney transplantation. Transpl Int 2013; 26 (Suppl 2):108.
39. Nijboer W, De Jonge1 J, Polak W, et al. Longer donor brain death causes decreased graft survival after liver transplantation. Transpl Int 2013; 26 (Suppl 2):120.
40. Kotsch K, Ulrich F, Reutzel-Selke A, et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. Ann Surg 2008; 248:1042-1050.
41. Goggins WC, Pascual MA, Powelson JA, et al. A prospective randomized clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76:798-802.
42. Mehrabi A, Mood ZhA, Sadeghi M, et al. Thymoglobulin and ischemia reperfusion injury in kidney and liver transplantation. Nephrol Dial Transplant 2007; 22 (Suppl 8):viii54-viii60.
43. Beiras-Fernandez A, Thein E, Chappel D, et al. Polyclonal antithymocyte globulins influence apoptosis in reperfused tissues after ischaemia in a nonhuman primate model. Transpl Int 2004; 17:453-457.
44. Chappell D, Beiras-Fernandez A, Hammer C, Thein E. In vivo visualization of the effect of polyclonal antithymocyte globulins on the microcirculation after ischemia/reperfusion in a primate model. Transplantation 2006; 81:552-558.
45. Brennan DC, Flavin K, Lowell JA, Howard TK. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67:1011-1018.
46. Bogetti D, Sankary HN, Jarzembowski TM, et al. Thymoglobulin induction protects liver allografts from ischemia/reperfusion injury. Clin Transplant 2005; 19:507-511.
47. Pré ville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71:460-468.
48. Yang J, Galipeau J, Kozak CA, et al. Mouse P-selectin glycoprotein ligand-1: molecular cloning, chromosomal localization, and expression of a functional Pselectin receptor. Blood 1996; 87:4176-4186.
49. Busuttil RW, Lipshutz GS, Kupiec-Weglinski JW, et al. rPSGL-Ig for improvement of early liver allograft function: a double-blind, placebo-controlled, single-center phase II study. Am J Transplant 2011; 11:786-797.
50. Dulkanchainun TS, Goss JA, Imagawa DK, et al. Reduction of hepatic ischemia/reperfusion injury by a soluble P-selectin glycoprotein ligand-1. Ann Surg 1998; 227:832-840.
51. Tsuchihashi S, Fondevila C, Shaw GD, et al. Molecular characterization of rat leukocyte P-selectin glycoprotein ligand-1 and effect of its blockade: protection from ischemia-reperfusion injury in liver transplantation. J Immunol 2006; 176:616-624.
52. Cavallari A, Cillo U, Nardo B, et al. A multicenter pilot prospective study comparing Celsior and University of Wisconsin preserving solutions for use in liver transplantation. Liver Transpl 2003; 9:814-821.
53. Guarrera JV, Estevez J, Boykin J, et al. Hypothermic machine perfusion of liver grafts for transplantation: technical development inhuman discard and miniature swine models. Transplant Proc 2005; 37:323-325.
54. Guarrera JV, Henry SD, Samstein B, et al. Hypothermic machine preservation in human liver transplantation: the first clinical series. Am J Transplant 2010; 10:372-381.
55. Henry SD, Nachber E, Tulipan J, et al. Hypothermic machine preservation reduces molecular markers of ischemia/reperfusion injury in human liver transplantation. Am J Transplant 2012; 12:2477-2486.
56. Butler AJ, Rees MA, Wight DG, et al. Successful extracorporeal porcine liver perfusion for 72 hr. Transplantation 2002; 73:1212-1218.
57. Schön MR, Kollmar O, Wolf S, et al. Liver transplantation after organ preservation with normothermic extracorporeal perfusion. Ann Surg 2001; 233:114-123.
58. Brockmann J, Reddy S, Coussios C, et al. Normothermic perfusion: a new paradigm for organ preservation. Ann Surg 2009; 250:1-6.
59. Baskin-Bey ES, Washburn K, Feng S, et al. Clinical trial of the Pan-Caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant 2007; 7:218-225.
60. Alvarado-Kristensson M, Melander F, Leandersson K, et al. Mp38-MAPK signals survival by phosphorylation of caspase-8 and caspase-3 in human neutrophils. J Exp Med 2004; 199:449-458.
61. Lang JD Jr, Teng X, Chumley P, et al. Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest 2007; 117:2583-2591.
62. US National Library of Medicine. ClinicalTrials.gov. 2012 [online], http://clinicaltrials.gov/ct2/results?term=NCT01172691. [Accessed 25 November 2013]
63. US National Library of Medicine. ClinicalTrials.gov. 2012 [online], http://clinicaltrials.gov/ct2/results?term=NCT00582010. [Accessed 25 November 2013]
64. Oltean M, Pullerits R, Zhu C, et al. Donor pretreatment with FK506 reduces reperfusion injury and accelerates intestinal graft recovery in rats. Surgery 2007; 141: 667.
65. Pratschke S, Bilzer M, Grützner U, et al. Tacrolimus preconditioning of rat liver allografts impacts glutathione homeostasis and early reperfusion injury. J Surg Res 2012; 176:309-316.
66. Kawano K, Bowers JL, Clouse ME. Protective effect of FK 506 on hepatic injury following cold ischemic preservation and transplantation: influence on hepatic microcirculation. Transplant Proc 1995; 2:362-363.
67. Garcia-Criado FJ, Palma-Vargas JM, Valdunciel-Garcia JJ, et al. Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. Transplantation 1997; 2:594-598.
68. Kristo I, Wilflingseder J, Kainz A, et al. Effect of intraportal infusion of tacrolimus on ischaemic reperfusion injury in orthotopic liver transplantation: a randomized controlled trial. Transpl Int 2011; 24:912-919.